Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Companyโs main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
์ข
๋ชฉ ์ฝ๋ ADAG
ํ์ฌ ์ด๋ฆAdagene Inc
์์ฅ์ผFeb 09, 2021
CEOLuo (Peter)
์ง์ ์138
์ ํDepository Receipt
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 09
์ฃผ์4F, Building C14, No. 218, Xinghu Street
๋์SUZHOU
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐChina
์ฐํธ ๋ฒํธ- -
์ ํ8651287773632
์น์ฌ์ดํธhttps://www.adagene.com/
์ข
๋ชฉ ์ฝ๋ ADAG
์์ฅ์ผFeb 09, 2021
CEOLuo (Peter)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์